No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Erasca, Inc. (ERAS) stock was $14.55 as of Oct 6, 2026, 10:00 AM EDT, down 1.15% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +503.1% · 3-year avg +90.8%/yr · 5-year avg -8.3%/yr
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway.
Biotechnology · San Diego, CA
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.14
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.14
vs Estimate
$-0.11
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ERAS | $5.05B | $14.55 | -1.15% | +503.05% | -8.34% | N/A | N/A |
| 2BLLN | $4.98B | $108.34 | -0.66% | N/A | N/A | N/A | vs ERAS |
| 3MMSI | $5.13B | $85.89 | -1.43% | +3.46% | +3.88% | +13.48% | vs ERAS |
| 4SRRK | $5.15B | $43.00 | -0.92% | +15.74% | +8.20% | N/A | vs ERAS |
| 5MIRM | $4.90B | $80.32 | -1.36% | +11.57% | +37.24% | N/A | vs ERAS |
| 6DNTH | $4.88B | $87.31 | -0.83% | +150.87% | -5.50% | N/A | vs ERAS |
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 9 analysts
Average Price Target
$24.11
+65.7% upside
Low
$20.00
Current
$14.55
High
$33.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.13 | $-0.13 | $-0.12 | 7 |
| Quarter ending Dec 2026 | $-0.15 | $-0.13 | $-0.12 | 6 |
| Quarter ending Mar 2027 | $-0.13 | $-0.13 | $-0.13 | 2 |
| Quarter ending Jun 2027 | $-0.15 | $-0.15 | $-0.15 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.04 | $-0.97 | $-0.94 | 7 |
| FY 2027 | $-0.74 | $-0.62 | $-0.55 | 7 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $7.52M | $7.52M | $7.52M | 5 |
| FY 2027 | $375000.00 | $375000.00 | $375000.00 | 4 |
